KROS240816C50000
- 6.10
- 0.000.00%
Keros Therapeutics Newsroom
Keros Therapeutics Analyst Ratings
Truist Securities Maintains Buy on Keros Therapeutics, Maintains $100 Price Target
Keros Therapeutics Analyst Ratings
Analysts' Top Healthcare Picks: Revolution Medicines (RVMD), Keros Therapeutics (KROS)
Keros Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Keros Therapeutics, Maintains $100 Price Target
Buy Rating Reaffirmed for Keros Therapeutics as KER-050 Advances Towards Phase 3 for MDS Treatment
Analysts' Top Healthcare Picks: Ascendis Pharma (ASND), Keros Therapeutics (KROS)
Buy Rating Affirmed for Keros Therapeutics: Promising Pipeline and Strong Financial Health
Buy Rating Affirmed for Keros Therapeutics Amid FDA Approval Landscape and Market Opportunity for KER-012
Keros Therapeutics Analyst Ratings
Analysts Have Conflicting Sentiments on These Healthcare Companies: Argenx Se (ARGX), Iridex (IRIX) and Keros Therapeutics (KROS)
Piper Sandler Sticks to Its Buy Rating for Keros Therapeutics (KROS)
Strong Buy Rating for Keros Therapeutics Amid Favorable LR-MDS Treatment Landscape and Regulatory Environment
Keros Therapeutics Analyst Ratings
Truist Financial Sticks to Their Buy Rating for Keros Therapeutics (KROS)
Keros Therapeutics (KROS) Gets a Buy From Truist Financial
Keros Therapeutics Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Keros Therapeutics (KROS), Veeva Systems (VEEV) and Capricor Therapeutics (CAPR)
Buy Rating Justified by Keros Therapeutics' Clinical Advancements and Strong Financial Position